FLYBRAINRobinhood
Thesis spike· back Sep 10·
20 people in 60 minutes17 FOMO theses + 8 pump.fun callouts
- 1
Mfs put a fly in the trenches
- 2
buy da main black men
FDV$8.28MSep 13since call+2,401.9%peak 169.11×
Thousands of people post their theses on FOMO and pump.fun every day. sniff reads them all, calls a token when enough people are talking, then prices the call on the spot and keeps score.
sniff hears a token the moment enough real wallets are talking about it, analyses it, and says why.
Thousands of traders post on FOMO and pump.fun day and night. The post that says something real reaches you as it's written — who said it, where, and what the market did next.
4,468 traders on the record so far.
PURRSolana
Interesting thesis· first call·
Interesting thesis
Since pointfarmcap has no cash left, they are trying to support the stock by selling off all their tokens... that must be terrifying for them...
FDV$3.11M4h agosince call+2,335.7%peak 169.34×
Stocks by price, tokens by market cap: a call is graded from the moment it's made, and any call leaves as a card for X or the group chat.
That card is drawn from live figures, exactly as it leaves the site.
Podcasts, livestreams, substacks, X. Every call is pulled out, timestamped and written down.
43 shows · 5,399 calls on tape, and counting.
a 2h 07m podcast→ 4 calls
a 3h 44m stream→ 2 calls
a week of tweets→ 3 calls
Sunday’s letter→ 1 call
The price is locked mid-broadcast, before anyone can round the story up.
A real card: Steve Eisman's desk, this week's episode.
Novo Nordisk is losing the diet drug war, suffering a 20% EPS decline with no sign its new GLP-1 pill is closing the gap.
“...and Novo Nordisk reported 475, down 20%. Now, Novo is trying to catch up with this new GLP-1 pill, but there is no indication that this is closing the gap.”
@The Real Eisman Playbook · Steve Eisman
NVOSHORT@ $46.57
$38.19+17.99%
since call Aug 7
peak +18.0%
The scoreboard says who's been right. Follow them, and their next call arrives priced.
